|
Would you be interested in a clinical trial for Semaglutide, a cardiovascular drug developed by Novo Nordisk? Roodeport Medicross Clinical Research Centre (Johannesburg, South Africa) is handling the clinical trial.
If you participate, there is 50% chance you will get Semaglutide, or get a harmless placebo to help the team evaluate whether semaglutide will reduce Cardiovascular risk disease and mortality in subjects with an established cardiovascular event (stroke or heart attack)and overweight or obesity. Roodeport Medicross Clinical Research Centre will make sure the process is smooth and safe for you.
If interested, please email: Annelise.ahir@medicross.co.za to enroll.
If you had a stroke/heart attack and are overweight, then give this a try.
Roodeport Medicross Clinical Research Centre has 15 years of existence and keeping with International Good Clinical Practise guidelines as well as SA GCP as well as Pharma Ethics Ethical Guidelines, we are not allowed to pay or incentivize either participating subjects or referring physicians. The only reimbursement we are allowed is for patient’s travel, sustenance and time. We are allowed to reimburse for patient’s travel, sustenance and time. |
